NIH R01 · 2025
PROJECT SUMMARY Drug-resistant tuberculosis (TB) is a major global epidemic and poses a particular threat to people living with HIV. With limited effective drugs available for treatment, multidrug-, and extensively drug-resistant TB carry a high mortality rate and threaten global TB and HIV control efforts. New and repurposed medications have recently been found to improve survival and cure rates. Linezolid— a drug initially developed for the treatment of Gram-positive infections—has considerable anti-TB activity and has been at the center of this treatment revolution. Since 2018, WHO has recommended that all rifampin- resistant (RR-TB) TB treatment regimens include linezolid. When given…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.